<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566527</url>
  </required_header>
  <id_info>
    <org_study_id>V221-038</org_study_id>
    <secondary_id>MRV02C</secondary_id>
    <nct_id>NCT00566527</nct_id>
  </id_info>
  <brief_title>Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)</brief_title>
  <official_title>An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary study objectives are:

        -  To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human
           Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age
           at the time of Dose 1 is as immunogenic as in healthy children of 12 months of age at
           the time of Dose 1.

        -  To demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval
           to healthy children of 9 months of age at the time of Dose 1 is as immunogenic as in
           healthy children of 12 months of age at the time of Dose 1.

        -  To demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval
           to healthy children of 11 months of age and 9 months of age at the time of Dose 1 is
           well-tolerated compared to children of 12 months of age at the time of Dose 1.

      The first primary hypothesis was that a 2-dose regimen of ProQuad® rHA, administered at a
      3-month interval to children of 11 months of age, would be non-inferior in terms of antibody
      response rates to measles, mumps, rubella, and varicella at Day 42 following Dose 2, to the
      same regimen in children of 12 months of age at the time of Dose 1.

      If the first primary hypothesis was demonstrated, the second primary hypothesis was that a
      2-dose regimen of ProQuad® rHA, administered at a 3-month interval to children of 9 months of
      age, would be non-inferior in terms of antibody response rates to measles, mumps, rubella,
      and varicella at Day 42 following Dose 2, to the same regimen in children of 12 months of age
      at the time of Dose 1.

      The secondary study objectives are:

        -  To describe the antibody titres to measles, mumps, rubella and varicella at Day 42
           following Dose 1 and Dose 2 of ProQuad® rHA administered to healthy children from 9
           months of age.

        -  To evaluate the safety profile of Dose 1 and Dose 2 of ProQuad® rHA administered to
           healthy children from 9 months of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2007</start_date>
  <completion_date type="Actual">December 29, 2008</completion_date>
  <primary_completion_date type="Actual">December 29, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in Arm 2 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2</measure>
    <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
    <description>Immunogenicity response rates were compared in participants with baseline seronegativity from Arm 2 (received ProQuad® Dose 1 at 11 months) and Arm 3 (received ProQuad® Dose 1 at 12 months). Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA). Response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre &lt;255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre &lt;10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre &lt;10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre &lt;1.25 gpELISA units/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in Arm 1 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2</measure>
    <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
    <description>Immunogenicity response rates were compared in participants with baseline seronegativity from Arm 1 (received ProQuad® Dose 1 at 9 months) and Arm 3 (received ProQuad® Dose 1 at 12 months). Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre &lt;255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre &lt;10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre &lt;10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre &lt;1.25 gpELISA units/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Injection-site Adverse Reactions</measure>
    <time_frame>Day 1 to Day 4 (up to 4 days after ProQuad® Dose 1)</time_frame>
    <description>The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Unsolicited Injection-site Adverse Reactions</measure>
    <time_frame>Up to Day 28 (up to 28 days after ProQuad® Dose 1)</time_frame>
    <description>The percentage of participants with unsolicited injection-site reactions after ProQuad® Dose 1 was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Systemic Adverse Event After ProQuad® Dose 1</measure>
    <time_frame>Up to Day 28 (up to 28 days after ProQuad® Dose 1)</time_frame>
    <description>The percentage of participants with systemic adverse events after ProQuad® Dose 1 was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Rectal (or Rectal Equivalent) Temperature ≥ 39.4°C</measure>
    <time_frame>Up to Day 28 (up to 28 days after ProQuad® Dose 1)</time_frame>
    <description>The percentage of participants with a rectal (or rectal equivalent) temperature ≥ 39.4°C after ProQuad® Dose 1 was determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titres (GMT) to Measles, Mumps, Rubella, and Varicella After ProQuad® Dose 1</measure>
    <time_frame>Day 42 (6 weeks after ProQuad® Dose 1)</time_frame>
    <description>Antibody titres (GMT) to measles, mumps, rubella, and varicella were determined after the first ProQuad® dose in participants with seronegative baseline values. Baseline seronegativity criteria were as follows: measles antibody titre &lt;255 mIU/mL; mumps antibody titre &lt;10 ELISA Ab units mL; rubella antibody titre &lt;10 IU/mL; and varicella antibody titre &lt;1.25 gpELISA units/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT to Measles, Mumps, Rubella, and Varicella After ProQuad® Dose 2</measure>
    <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
    <description>Antibody titres (GMT) to measles, mumps, rubella, and varicella were determined after the second ProQuad® dose in participants with seronegative baseline values. Baseline seronegativity criteria were as follows: measles antibody titre &lt;255 mIU/mL; mumps antibody titre &lt;10 ELISA Ab units mL; rubella antibody titre &lt;10 IU/mL; and varicella antibody titre &lt;1.25 gpELISA units/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Varicella Antibody Titre ≥ 1.25 gpELISA Units/mL</measure>
    <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
    <description>The percentage of participants with varicella antibody titre ≥ 1.25 gpELISA units/mL 6 weeks after each ProQuad® dose was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Baseline Seronegative Participants Meeting Antibody Immunogenicity Response Criteria After ProQuad® Dose 1</measure>
    <time_frame>Day 42 (6 weeks after ProQuad® Dose 1)</time_frame>
    <description>The percentage of baseline seronegative participants meeting measles, mumps, rubella, and varicella antibody response criteria after the first ProQuad® dose was determined. Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre &lt;255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre &lt;10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre &lt;10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre &lt;1.25 gpELISA units/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Non-injection Site Rashes of Interest Following ProQuad® Dose 1</measure>
    <time_frame>Up to Day 28 (up to 4 weeks after ProQuad® Dose 1)</time_frame>
    <description>The percentage of participants with rashes of interest after ProQuad® Dose 1 was determined. Rashes of interest consisted of measles-like rash, rubella-like rash, varicella-like rash, zoster-like rash, and mumps-like rash.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Non-injection Site Rashes of Interest Following ProQuad® Dose 2</measure>
    <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
    <description>The percentage of participants with rashes of interest after receiving ProQuad® Dose 2 was determined. Rashes of interest consisted of measles-like rash, rubella-like rash, varicella-like rash, zoster-like rash, and mumps-like rash.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1620</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>Arm 1: ProQuad® at 9 and 12 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: ProQuad® at 11 and 14 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 at 14 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: ProQuad at 12 and 15 months</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 at 15 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProQuad® manufactured with recombinant Human Albumin (rHA)</intervention_name>
    <description>A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).</description>
    <arm_group_label>Arm 1: ProQuad® at 9 and 12 months</arm_group_label>
    <arm_group_label>Arm 2: ProQuad® at 11 and 14 months</arm_group_label>
    <arm_group_label>Arm 3: ProQuad at 12 and 15 months</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy subject of either gender of 9 months of age

          2. Negative clinical history of measles, mumps, rubella, varicella or zoster

          3. Informed consent form signed by both parents or legal representative

          4. Parent(s) or legal representative able to attend all the scheduled visits with the
             subject and to understand and comply with the study procedures

          5. Both parent or legal representative are over 18 years of age

          6. Subject is affiliated to a health social security system

        Exclusion Criteria:

          1. Febrile illness in the previous 3 days

          2. Prior vaccination with a measles, mumps, rubella and/or varicella vaccine either alone
             or in any combination

          3. Exposure to measles, mumps, rubella, varicella and/or zoster in the previous 30 days

          4. Tuberculin test done in the previous 2 days

          5. Severe chronic disease

          6. Known active tuberculosis

          7. Known personal history of encephalopathy, seizure disorder or progressive, evolving or
             unstable neurological condition

          8. Hereditary problems of fructose intolerance

          9. Prior known sensitivity or allergy to any component of the vaccine

         10. Known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms
             affecting the bone marrow or lymphatic systems

         11. Humoral or cellular immunodeficiency,

         12. Immunosuppressive therapy [including systemic corticosteroids (a), given daily or on
             alternate days at high doses (&gt;=2 mg/kg/day prednisone equivalent or &gt;=20 mg/day if
             the subject's weight was &gt;10 kg) during at least 14 days in the previous 30 days]

         13. Family history of congenital or hereditary immunodeficiency

         14. Receipt of immunoglobulins or blood-derived products in the previous 150 days or
             scheduled to be administered through Visit 5

         15. Receipt of an inactivated vaccine in the previous 14 days

         16. Receipt of a live non-study vaccine in the previous 28 days

         17. Any medical condition which, in the opinion of the investigator, might have interfered
             with the evaluation of the study objectives

         18. Current participation or scheduled participation in any other clinical study through
             Visit 5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>SPMSD</affiliation>
  </overall_official>
  <removed_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <results_first_submitted>October 4, 2017</results_first_submitted>
  <results_first_submitted_qc>January 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2018</results_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rubella</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pediatric participants from 9 to 12 months of age at the start of the study were recruited at 48 study centers in Finland, France, and Germany.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: ProQuad® at 9 and 12 Months</title>
          <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: ProQuad® at 11 and 14 Months</title>
          <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: ProQuad® at 12 and 15 Months</title>
          <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="541">Number randomized.</participants>
                <participants group_id="P2" count="540">Number randomized.</participants>
                <participants group_id="P3" count="539">Number randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received ProQuad® Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="529"/>
                <participants group_id="P2" count="484"/>
                <participants group_id="P3" count="470"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received ProQuad® Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="525"/>
                <participants group_id="P2" count="478"/>
                <participants group_id="P3" count="462"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="524"/>
                <participants group_id="P2" count="474"/>
                <participants group_id="P3" count="461"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Reason not provided</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: ProQuad® at 9 and 12 Months</title>
          <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: ProQuad® at 11 and 14 Months</title>
          <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: ProQuad® at 12 and 15 Months</title>
          <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="541"/>
            <count group_id="B2" value="540"/>
            <count group_id="B3" value="539"/>
            <count group_id="B4" value="1620"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at inclusion in study.</description>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.47" spread="0.29"/>
                    <measurement group_id="B2" value="9.48" spread="0.30"/>
                    <measurement group_id="B3" value="9.47" spread="9.43"/>
                    <measurement group_id="B4" value="9.48" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="258"/>
                    <measurement group_id="B4" value="821"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="259"/>
                    <measurement group_id="B3" value="281"/>
                    <measurement group_id="B4" value="799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Arm 2 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2</title>
        <description>Immunogenicity response rates were compared in participants with baseline seronegativity from Arm 2 (received ProQuad® Dose 1 at 11 months) and Arm 3 (received ProQuad® Dose 1 at 12 months). Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA). Response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre &lt;255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre &lt;10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre &lt;10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre &lt;1.25 gpELISA units/mL.</description>
        <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
        <population>All baseline seronegative participants with immunogenicity data are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Arm 2 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2</title>
          <description>Immunogenicity response rates were compared in participants with baseline seronegativity from Arm 2 (received ProQuad® Dose 1 at 11 months) and Arm 3 (received ProQuad® Dose 1 at 12 months). Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA). Response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre &lt;255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre &lt;10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre &lt;10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre &lt;1.25 gpELISA units/mL.</description>
          <population>All baseline seronegative participants with immunogenicity data are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="440"/>
                    <count group_id="O2" value="434"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="96.2" upper_limit="99.1"/>
                    <measurement group_id="O2" value="98.8" lower_limit="97.3" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="436"/>
                    <count group_id="O2" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="98.4" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="98.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.4" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="347"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Measles difference</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared when the lower bound of the 95% CI was &gt; -5. Values are shown as percentages.</non_inferiority_desc>
            <param_type>Measles Response Rate (Arm 2 - Arm 3)</param_type>
            <param_value>-0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.82</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mumps difference</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared when the lower bound of the 95% CI was &gt; -5. Values are shown as percentages.</non_inferiority_desc>
            <param_type>Mumps Response Rate (Arm 2 - Arm 3)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.20</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rubella difference</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared when the lower bound of the 95% CI was &gt; -5. Values are shown as percentages.</non_inferiority_desc>
            <param_type>Rubella Response Rate (Arm 2 - Arm 3)</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.55</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Varicella difference</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared when the lower bound of the 95% CI was &gt; -10. Values are shown as percentages.</non_inferiority_desc>
            <param_type>Varicella Response Rate (Arm 2 - Arm 3)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Arm 1 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2</title>
        <description>Immunogenicity response rates were compared in participants with baseline seronegativity from Arm 1 (received ProQuad® Dose 1 at 9 months) and Arm 3 (received ProQuad® Dose 1 at 12 months). Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre &lt;255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre &lt;10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre &lt;10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre &lt;1.25 gpELISA units/mL.</description>
        <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
        <population>All baseline seronegative participants with immunogenicity data are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Arm 1 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2</title>
          <description>Immunogenicity response rates were compared in participants with baseline seronegativity from Arm 1 (received ProQuad® Dose 1 at 9 months) and Arm 3 (received ProQuad® Dose 1 at 12 months). Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre &lt;255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre &lt;10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre &lt;10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre &lt;1.25 gpELISA units/mL.</description>
          <population>All baseline seronegative participants with immunogenicity data are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="434"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="92.6" upper_limit="96.7"/>
                    <measurement group_id="O2" value="98.8" lower_limit="97.3" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="484"/>
                    <count group_id="O2" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.9" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="500"/>
                    <count group_id="O2" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="98.3" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.4" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="347"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Measles difference</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared when the lower bound of the 95% CI was &gt; -5. Values are shown as percentages.</non_inferiority_desc>
            <param_type>Measles Response Rate (Arm 1 - Arm 3)</param_type>
            <param_value>-3.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.44</ci_lower_limit>
            <ci_upper_limit>-1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mumps difference</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared when the lower bound of the 95% CI was &gt; -5. Values are shown as percentages.</non_inferiority_desc>
            <param_type>Mumps Response Rate (Arm 1 - Arm 3)</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.71</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rubella difference</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared when the lower bound of the 95% CI was &gt; -5. Values are shown as percentages.</non_inferiority_desc>
            <param_type>Rubella Response Rate (Arm 1 - Arm 3)</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.34</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Varicella difference</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared when the lower bound of the 95% CI was &gt; -10. Values are shown as percentages.</non_inferiority_desc>
            <param_type>Varicella Response Rate (Arm 1 - Arm 3)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Injection-site Adverse Reactions</title>
        <description>The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 1.</description>
        <time_frame>Day 1 to Day 4 (up to 4 days after ProQuad® Dose 1)</time_frame>
        <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Injection-site Adverse Reactions</title>
          <description>The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 1.</description>
          <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="11.5" upper_limit="17.7"/>
                    <measurement group_id="O2" value="15.4" lower_limit="12.3" upper_limit="19.0"/>
                    <measurement group_id="O3" value="17.2" lower_limit="13.9" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="8.8" upper_limit="14.4"/>
                    <measurement group_id="O2" value="10.4" lower_limit="7.8" upper_limit="13.5"/>
                    <measurement group_id="O3" value="13.7" lower_limit="10.7" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.2" upper_limit="3.9"/>
                    <measurement group_id="O2" value="4.6" lower_limit="2.9" upper_limit="6.9"/>
                    <measurement group_id="O3" value="2.4" lower_limit="1.2" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing Unsolicited Injection-site Adverse Reactions</title>
        <description>The percentage of participants with unsolicited injection-site reactions after ProQuad® Dose 1 was determined.</description>
        <time_frame>Up to Day 28 (up to 28 days after ProQuad® Dose 1)</time_frame>
        <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Unsolicited Injection-site Adverse Reactions</title>
          <description>The percentage of participants with unsolicited injection-site reactions after ProQuad® Dose 1 was determined.</description>
          <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="21.2" upper_limit="28.7"/>
                    <measurement group_id="O2" value="23.3" lower_limit="19.6" upper_limit="27.4"/>
                    <measurement group_id="O3" value="19.1" lower_limit="15.6" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Systemic Adverse Event After ProQuad® Dose 1</title>
        <description>The percentage of participants with systemic adverse events after ProQuad® Dose 1 was determined.</description>
        <time_frame>Up to Day 28 (up to 28 days after ProQuad® Dose 1)</time_frame>
        <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Systemic Adverse Event After ProQuad® Dose 1</title>
          <description>The percentage of participants with systemic adverse events after ProQuad® Dose 1 was determined.</description>
          <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="67.9" upper_limit="75.8"/>
                    <measurement group_id="O2" value="71.9" lower_limit="67.6" upper_limit="75.9"/>
                    <measurement group_id="O3" value="71.9" lower_limit="67.6" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Rectal (or Rectal Equivalent) Temperature ≥ 39.4°C</title>
        <description>The percentage of participants with a rectal (or rectal equivalent) temperature ≥ 39.4°C after ProQuad® Dose 1 was determined.</description>
        <time_frame>Up to Day 28 (up to 28 days after ProQuad® Dose 1)</time_frame>
        <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rectal (or Rectal Equivalent) Temperature ≥ 39.4°C</title>
          <description>The percentage of participants with a rectal (or rectal equivalent) temperature ≥ 39.4°C after ProQuad® Dose 1 was determined.</description>
          <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="6.5" upper_limit="11.5"/>
                    <measurement group_id="O2" value="10.3" lower_limit="7.7" upper_limit="13.4"/>
                    <measurement group_id="O3" value="14.8" lower_limit="11.7" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titres (GMT) to Measles, Mumps, Rubella, and Varicella After ProQuad® Dose 1</title>
        <description>Antibody titres (GMT) to measles, mumps, rubella, and varicella were determined after the first ProQuad® dose in participants with seronegative baseline values. Baseline seronegativity criteria were as follows: measles antibody titre &lt;255 mIU/mL; mumps antibody titre &lt;10 ELISA Ab units mL; rubella antibody titre &lt;10 IU/mL; and varicella antibody titre &lt;1.25 gpELISA units/mL.</description>
        <time_frame>Day 42 (6 weeks after ProQuad® Dose 1)</time_frame>
        <population>All participants with seronegative baselines who received ProQuad® Dose 1 and have immunogenicity data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titres (GMT) to Measles, Mumps, Rubella, and Varicella After ProQuad® Dose 1</title>
          <description>Antibody titres (GMT) to measles, mumps, rubella, and varicella were determined after the first ProQuad® dose in participants with seronegative baseline values. Baseline seronegativity criteria were as follows: measles antibody titre &lt;255 mIU/mL; mumps antibody titre &lt;10 ELISA Ab units mL; rubella antibody titre &lt;10 IU/mL; and varicella antibody titre &lt;1.25 gpELISA units/mL.</description>
          <population>All participants with seronegative baselines who received ProQuad® Dose 1 and have immunogenicity data available are included.</population>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="460"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles (mIU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="508"/>
                    <count group_id="O2" value="455"/>
                    <count group_id="O3" value="438"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="942" lower_limit="808" upper_limit="1098"/>
                    <measurement group_id="O2" value="1977" lower_limit="1736" upper_limit="2252"/>
                    <measurement group_id="O3" value="2500" lower_limit="2199" upper_limit="2841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps (ELISA Ab units/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                    <count group_id="O2" value="453"/>
                    <count group_id="O3" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="68" upper_limit="79"/>
                    <measurement group_id="O2" value="91" lower_limit="84" upper_limit="99"/>
                    <measurement group_id="O3" value="86" lower_limit="79" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella (IU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="518"/>
                    <count group_id="O2" value="460"/>
                    <count group_id="O3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="60" upper_limit="70"/>
                    <measurement group_id="O2" value="77" lower_limit="71" upper_limit="83"/>
                    <measurement group_id="O3" value="81" lower_limit="75" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella (gpELISA units/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="13" upper_limit="16"/>
                    <measurement group_id="O2" value="15" lower_limit="14" upper_limit="16"/>
                    <measurement group_id="O3" value="15" lower_limit="14" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT to Measles, Mumps, Rubella, and Varicella After ProQuad® Dose 2</title>
        <description>Antibody titres (GMT) to measles, mumps, rubella, and varicella were determined after the second ProQuad® dose in participants with seronegative baseline values. Baseline seronegativity criteria were as follows: measles antibody titre &lt;255 mIU/mL; mumps antibody titre &lt;10 ELISA Ab units mL; rubella antibody titre &lt;10 IU/mL; and varicella antibody titre &lt;1.25 gpELISA units/mL.</description>
        <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
        <population>All participants with seronegative baselines who received ProQuad® Dose 2 and have immunogenicity data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT to Measles, Mumps, Rubella, and Varicella After ProQuad® Dose 2</title>
          <description>Antibody titres (GMT) to measles, mumps, rubella, and varicella were determined after the second ProQuad® dose in participants with seronegative baseline values. Baseline seronegativity criteria were as follows: measles antibody titre &lt;255 mIU/mL; mumps antibody titre &lt;10 ELISA Ab units mL; rubella antibody titre &lt;10 IU/mL; and varicella antibody titre &lt;1.25 gpELISA units/mL.</description>
          <population>All participants with seronegative baselines who received ProQuad® Dose 2 and have immunogenicity data available are included.</population>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="445"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles (mIU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="440"/>
                    <count group_id="O3" value="434"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1817" lower_limit="1645" upper_limit="2006"/>
                    <measurement group_id="O2" value="2320" lower_limit="2129" upper_limit="2529"/>
                    <measurement group_id="O3" value="2703" lower_limit="2492" upper_limit="2933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps (ELISA Ab units/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="481"/>
                    <count group_id="O2" value="436"/>
                    <count group_id="O3" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" lower_limit="147" upper_limit="168"/>
                    <measurement group_id="O2" value="163" lower_limit="151" upper_limit="175"/>
                    <measurement group_id="O3" value="172" lower_limit="159" upper_limit="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella (IU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="500"/>
                    <count group_id="O2" value="445"/>
                    <count group_id="O3" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" lower_limit="99" upper_limit="113"/>
                    <measurement group_id="O2" value="116" lower_limit="109" upper_limit="124"/>
                    <measurement group_id="O3" value="118" lower_limit="111" upper_limit="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella {gpELISA units/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="347"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431" lower_limit="372" upper_limit="500"/>
                    <measurement group_id="O2" value="460" lower_limit="410" upper_limit="517"/>
                    <measurement group_id="O3" value="515" lower_limit="466" upper_limit="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Varicella Antibody Titre ≥ 1.25 gpELISA Units/mL</title>
        <description>The percentage of participants with varicella antibody titre ≥ 1.25 gpELISA units/mL 6 weeks after each ProQuad® dose was determined.</description>
        <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
        <population>All participants who received ProQuad® and have serology results are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Varicella Antibody Titre ≥ 1.25 gpELISA Units/mL</title>
          <description>The percentage of participants with varicella antibody titre ≥ 1.25 gpELISA units/mL 6 weeks after each ProQuad® dose was determined.</description>
          <population>All participants who received ProQuad® and have serology results are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="474"/>
                <count group_id="O3" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ProQuad® Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="523"/>
                    <count group_id="O2" value="474"/>
                    <count group_id="O3" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.8" lower_limit="98.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ProQuad® Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="521"/>
                    <count group_id="O2" value="469"/>
                    <count group_id="O3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="99.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Baseline Seronegative Participants Meeting Antibody Immunogenicity Response Criteria After ProQuad® Dose 1</title>
        <description>The percentage of baseline seronegative participants meeting measles, mumps, rubella, and varicella antibody response criteria after the first ProQuad® dose was determined. Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre &lt;255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre &lt;10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre &lt;10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre &lt;1.25 gpELISA units/mL.</description>
        <time_frame>Day 42 (6 weeks after ProQuad® Dose 1)</time_frame>
        <population>All baseline seronegative participants with immunogenicity data are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Baseline Seronegative Participants Meeting Antibody Immunogenicity Response Criteria After ProQuad® Dose 1</title>
          <description>The percentage of baseline seronegative participants meeting measles, mumps, rubella, and varicella antibody response criteria after the first ProQuad® dose was determined. Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre &lt;255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre &lt;10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre &lt;10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre &lt;1.25 gpELISA units/mL.</description>
          <population>All baseline seronegative participants with immunogenicity data are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="460"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="508"/>
                    <count group_id="O2" value="455"/>
                    <count group_id="O3" value="438"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" lower_limit="68.5" upper_limit="76.5"/>
                    <measurement group_id="O2" value="87.9" lower_limit="84.6" upper_limit="90.8"/>
                    <measurement group_id="O3" value="90.2" lower_limit="87.0" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                    <count group_id="O2" value="453"/>
                    <count group_id="O3" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="94.6" upper_limit="98.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="97.1" upper_limit="99.5"/>
                    <measurement group_id="O3" value="98.3" lower_limit="96.6" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="518"/>
                    <count group_id="O2" value="460"/>
                    <count group_id="O3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="96.0" upper_limit="98.8"/>
                    <measurement group_id="O2" value="98.9" lower_limit="97.5" upper_limit="99.6"/>
                    <measurement group_id="O3" value="98.0" lower_limit="96.2" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="91.2" upper_limit="97.5"/>
                    <measurement group_id="O2" value="97.8" lower_limit="95.4" upper_limit="99.1"/>
                    <measurement group_id="O3" value="97.5" lower_limit="95.2" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Non-injection Site Rashes of Interest Following ProQuad® Dose 1</title>
        <description>The percentage of participants with rashes of interest after ProQuad® Dose 1 was determined. Rashes of interest consisted of measles-like rash, rubella-like rash, varicella-like rash, zoster-like rash, and mumps-like rash.</description>
        <time_frame>Up to Day 28 (up to 4 weeks after ProQuad® Dose 1)</time_frame>
        <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Non-injection Site Rashes of Interest Following ProQuad® Dose 1</title>
          <description>The percentage of participants with rashes of interest after ProQuad® Dose 1 was determined. Rashes of interest consisted of measles-like rash, rubella-like rash, varicella-like rash, zoster-like rash, and mumps-like rash.</description>
          <population>All participants who received ProQuad® Dose 1 and have safety follow-up data available are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.5" upper_limit="6.0"/>
                    <measurement group_id="O2" value="5.8" lower_limit="3.9" upper_limit="8.3"/>
                    <measurement group_id="O3" value="6.9" lower_limit="4.7" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.5" upper_limit="2.7"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.9" upper_limit="3.5"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0.6" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="3.6" upper_limit="7.6"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.4" upper_limit="6.1"/>
                    <measurement group_id="O3" value="6.4" lower_limit="4.4" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zoster-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps-like illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Non-injection Site Rashes of Interest Following ProQuad® Dose 2</title>
        <description>The percentage of participants with rashes of interest after receiving ProQuad® Dose 2 was determined. Rashes of interest consisted of measles-like rash, rubella-like rash, varicella-like rash, zoster-like rash, and mumps-like rash.</description>
        <time_frame>Day 132 (6 weeks after ProQuad® Dose 2)</time_frame>
        <population>All participants who received ProQuad® Dose 2 and have safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: ProQuad® at 9 and 12 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: ProQuad® at 11 and 14 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: ProQuad® at 12 and 15 Months</title>
            <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Non-injection Site Rashes of Interest Following ProQuad® Dose 2</title>
          <description>The percentage of participants with rashes of interest after receiving ProQuad® Dose 2 was determined. Rashes of interest consisted of measles-like rash, rubella-like rash, varicella-like rash, zoster-like rash, and mumps-like rash.</description>
          <population>All participants who received ProQuad® Dose 2 and have safety follow-up data available are included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="474"/>
                <count group_id="O3" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.1" upper_limit="3.7"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.5" upper_limit="4.6"/>
                    <measurement group_id="O3" value="2.8" lower_limit="1.5" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.7" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.9" upper_limit="3.6"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.2" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.1" upper_limit="3.7"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.3" upper_limit="5.9"/>
                    <measurement group_id="O3" value="2.6" lower_limit="1.3" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zoster-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps-like illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 146 days (up to 56 days after Dose 2)</time_frame>
      <desc>An adverse event is any untoward medical occurrence in a participant administered an investigational medicinal product (IMP) and which does not necessarily have a causal relationship with the IMP. Participants who received at least one dose of ProQuad® and have follow-up data available are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: ProQuad® at 9 and 12 Months</title>
          <description>Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 90 days later at 12 months of age.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: ProQuad® at 11 and 14 Months</title>
          <description>Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 90 days later at 14 months of age.</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: ProQuad® at 12 and 15 Months</title>
          <description>Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 90 days later at 15 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="541"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Norwalk virus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="541"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="468" subjects_at_risk="541"/>
                <counts group_id="E2" subjects_affected="430" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="401" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="71" subjects_affected="66" subjects_at_risk="541"/>
                <counts group_id="E2" events="77" subjects_affected="62" subjects_at_risk="540"/>
                <counts group_id="E3" events="72" subjects_affected="62" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="65" subjects_affected="44" subjects_at_risk="541"/>
                <counts group_id="E2" events="39" subjects_affected="28" subjects_at_risk="540"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="44" subjects_affected="37" subjects_at_risk="541"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="540"/>
                <counts group_id="E3" events="28" subjects_affected="23" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="383" subjects_affected="278" subjects_at_risk="541"/>
                <counts group_id="E2" events="350" subjects_affected="262" subjects_at_risk="540"/>
                <counts group_id="E3" events="322" subjects_affected="233" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="126" subjects_affected="99" subjects_at_risk="541"/>
                <counts group_id="E2" events="123" subjects_affected="100" subjects_at_risk="540"/>
                <counts group_id="E3" events="137" subjects_affected="109" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="117" subjects_affected="107" subjects_at_risk="541"/>
                <counts group_id="E2" events="100" subjects_affected="90" subjects_at_risk="540"/>
                <counts group_id="E3" events="92" subjects_affected="82" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="127" subjects_affected="77" subjects_at_risk="541"/>
                <counts group_id="E2" events="103" subjects_affected="70" subjects_at_risk="540"/>
                <counts group_id="E3" events="113" subjects_affected="86" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="117" subjects_affected="92" subjects_at_risk="541"/>
                <counts group_id="E2" events="133" subjects_affected="92" subjects_at_risk="540"/>
                <counts group_id="E3" events="99" subjects_affected="76" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="44" subjects_affected="40" subjects_at_risk="541"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="540"/>
                <counts group_id="E3" events="31" subjects_affected="27" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="541"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="540"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="58" subjects_affected="51" subjects_at_risk="541"/>
                <counts group_id="E2" events="51" subjects_affected="42" subjects_at_risk="540"/>
                <counts group_id="E3" events="42" subjects_affected="37" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="53" subjects_affected="45" subjects_at_risk="541"/>
                <counts group_id="E2" events="50" subjects_affected="46" subjects_at_risk="540"/>
                <counts group_id="E3" events="48" subjects_affected="41" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="127" subjects_affected="101" subjects_at_risk="541"/>
                <counts group_id="E2" events="110" subjects_affected="94" subjects_at_risk="540"/>
                <counts group_id="E3" events="99" subjects_affected="75" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="85" subjects_affected="70" subjects_at_risk="541"/>
                <counts group_id="E2" events="87" subjects_affected="68" subjects_at_risk="540"/>
                <counts group_id="E3" events="98" subjects_affected="76" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="43" subjects_affected="36" subjects_at_risk="541"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="540"/>
                <counts group_id="E3" events="27" subjects_affected="19" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="68" subjects_affected="61" subjects_at_risk="541"/>
                <counts group_id="E2" events="52" subjects_affected="45" subjects_at_risk="540"/>
                <counts group_id="E3" events="44" subjects_affected="40" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="541"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="540"/>
                <counts group_id="E3" events="40" subjects_affected="30" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="64" subjects_affected="52" subjects_at_risk="541"/>
                <counts group_id="E2" events="47" subjects_affected="37" subjects_at_risk="540"/>
                <counts group_id="E3" events="48" subjects_affected="41" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Rash morbilliform</sub_title>
                <counts group_id="E1" events="33" subjects_affected="32" subjects_at_risk="541"/>
                <counts group_id="E2" events="41" subjects_affected="39" subjects_at_risk="540"/>
                <counts group_id="E3" events="45" subjects_affected="41" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" events="39" subjects_affected="35" subjects_at_risk="541"/>
                <counts group_id="E2" events="40" subjects_affected="34" subjects_at_risk="540"/>
                <counts group_id="E3" events="43" subjects_affected="39" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sanofi Pasteur MSD shall have sixty days to review these documents and may refuse to give its consent in part or whole for confidential reasons (including but not limited to intellectual property rights, whether patentable or not).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

